These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 32563354)

  • 1. Rituximab in autoimmune pemphigoid diseases: Indications, optimized regimens, and practice gaps.
    Thomas RM; Colon A; Motaparthi K
    Clin Dermatol; 2020; 38(3):384-396. PubMed ID: 32563354
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness and Safety of Rituximab in Recalcitrant Pemphigoid Diseases.
    Lamberts A; Euverman HI; Terra JB; Jonkman MF; Horváth B
    Front Immunol; 2018; 9():248. PubMed ID: 29520266
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting interleukin 4 receptor α: A new approach to the treatment of cutaneous autoimmune bullous diseases?
    Russo R; Cozzani E; Gasparini G; Parodi A
    Dermatol Ther; 2020 Jan; 33(1):e13190. PubMed ID: 31863534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rituximab for treatment-refractory pemphigus and pemphigoid: a case series of 17 patients.
    Kasperkiewicz M; Shimanovich I; Ludwig RJ; Rose C; Zillikens D; Schmidt E
    J Am Acad Dermatol; 2011 Sep; 65(3):552-558. PubMed ID: 21641080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical outcome and safety of rituximab therapy for pemphigoid diseases.
    Tovanabutra N; Payne AS
    J Am Acad Dermatol; 2020 May; 82(5):1237-1239. PubMed ID: 31738960
    [No Abstract]   [Full Text] [Related]  

  • 6. A systematic review on efficacy, safety and treatment durability of intravenous immunoglobulin in autoimmune bullous dermatoses: Special focus on indication and combination therapy.
    Kianfar N; Dasdar S; Daneshpazhooh M; Aryanian Z; Goodarzi A
    Exp Dermatol; 2023 Jul; 32(7):934-944. PubMed ID: 37150538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rituximab Therapy for Mucous Membrane Pemphigoid: A Retrospective Monocentric Study With Long-Term Follow-Up in 109 Patients.
    Bohelay G; Alexandre M; Le Roux-Villet C; Sitbon I; Doan S; Soued I; Shourick J; Rousset L; Mellottee B; Heller M; Lièvre N; Zumelzu C; Morin F; Grootenboer-Mignot S; Gabison E; Caux F; Prost-Squarcioni C; Musette P
    Front Immunol; 2022; 13():915205. PubMed ID: 35844526
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rituximab in refractory autoimmune bullous diseases.
    Schmidt E; Hunzelmann N; Zillikens D; Bröcker EB; Goebeler M
    Clin Exp Dermatol; 2006 Jul; 31(4):503-8. PubMed ID: 16716150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. World Workshop of Oral Medicine VII: A systematic review of immunobiologic therapy for oral manifestations of pemphigoid and pemphigus.
    Mays JW; Carey BP; Posey R; Gueiros LA; France K; Setterfield J; Woo SB; Sollecito TP; Culton D; Payne AS; Greenberg MS; De Rossi S
    Oral Dis; 2019 Jun; 25 Suppl 1(Suppl 1):111-121. PubMed ID: 31140696
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Retrospective analysis of the long-term therapeutic effectiveness and safety profile of rituximab in the treatment of mucous membrane pemphigoid in a German university center between 2008 and 2019.
    Bamberger F; König IR; Gola D; Zillikens D; Sadik CD
    Front Immunol; 2023; 14():1180150. PubMed ID: 37143653
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment Update of Autoimmune Blistering Diseases.
    Kridin K; Ahn C; Huang WC; Ansari A; Sami N
    Dermatol Clin; 2019 Apr; 37(2):215-228. PubMed ID: 30850044
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Rituximab (anti-CD20) for the treatment of autoimmune bullous diseases].
    Kasperkiewicz M; Zillikens D
    Hautarzt; 2007 Feb; 58(2):115-6, 118-21. PubMed ID: 17237928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The blistering diseases.
    Scott JE; Ahmed AR
    Med Clin North Am; 1998 Nov; 82(6):1239-83. PubMed ID: 9889748
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autoimmune bullous diseases with skin and eye involvement: Cicatricial pemphigoid, pemphigus vulgaris, and pemphigus paraneoplastica.
    Broussard KC; Leung TG; Moradi A; Thorne JE; Fine JD
    Clin Dermatol; 2016; 34(2):205-13. PubMed ID: 26903186
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bullous Diseases.
    Corbaux C; Joly P
    Curr Probl Dermatol; 2018; 53():64-69. PubMed ID: 29131038
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The top 10 research priorities for the treatment of bullous pemphigoid, mucous membrane pemphigoid and pemphigus vulgaris in the UK: results of a James Lind Alliance Priority Setting Partnership.
    Harman KE; Barha J; Chalmers JR; Dart JKG; Davies I; Ellis P; Grindlay D; Hampton PJ; Hill S; Hockey S; Lloyd-Lavery A; McPhee M; Murphy R; Rauz S; Setterfield JF; Thompson I; Westmoreland M; Waistell C
    Br J Dermatol; 2023 Sep; 189(4):469-498. PubMed ID: 37201904
    [No Abstract]   [Full Text] [Related]  

  • 17. Autoimmune blistering diseases in the elderly.
    Parker SR; MacKelfresh J
    Clin Dermatol; 2011; 29(1):69-79. PubMed ID: 21146735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent advances in the understanding and treatment of pemphigus and pemphigoid.
    Yamagami J
    F1000Res; 2018; 7():. PubMed ID: 30228865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rituximab therapy of recalcitrant bullous dermatoses.
    Wollina U; Koch A; Hansel G
    J Dermatol Case Rep; 2008 Mar; 2(1):4-7. PubMed ID: 21886702
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual diagnosis of Pemphigus and pemphigoid. Retrospective review of thirty cases in the literature.
    Sami N; Ahmed AR
    Dermatology; 2001; 202(4):293-301. PubMed ID: 11455140
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.